The proportion of CD8 T cells within the tumor showed a significant increase (Figure 3C), while the proportion of DC cells did not show significant changes (Figure 3D). Gilteritinib, a FLT3 inhibitor, has been extensively studied in acute myeloid leukemia but has rarely been used in mouse tumors. This evidence concerns the gene CD8A and neoplasm.